The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia

Lucy C. Fox(Peter MacCallum Cancer Centre), Andrew Grigg(The Royal Melbourne Hospital), Shaun Fleming(Peter MacCallum Cancer Centre), Rosemary Harrup(University of Tasmania), Amy P. Holmes(Canberra Hospital), Sumita Ratnasingam(Monash Health), Kah Lok Chan, Rebecca Cleary(Princess Alexandra Hospital), Ben Costello(Baker Heart and Diabetes Institute), Asma Ashraf(Calvary Mater Newcastle Hospital), Kate Burbury(The University of Melbourne), Cecily Forsyth(Gosford Hospital), Jake Shortt(The University of Melbourne), Katherine D. Cummins(Parker Institute for Cancer Immunotherapy), Maciek Tatarczuch(Peter MacCallum Cancer Centre), Faye Putt(Austin Hospital), Wei‐Hsun Hsu(Royal Prince Alfred Hospital), Anthony P. Schwarer(The Alfred Hospital), David T Yeung(Royal Adelaide Hospital), Andrew McQuillan(Hollywood Orthopaedic Group), Olga Motorna(The University of Melbourne)
Blood Advances
May 15, 2017
10.1182/bloodadvances.2016003889
Cited by 42

Related Papers

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
|Blood|2013|705
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
|New England Journal of Medicine|2018|429
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
|Blood|2019|369
Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study
|Nature Medicine|2020|289